A
Auscan Bio / 澳斯康生物
Biologics CDMO and serum-free cell-culture media (Nantong)
About Auscan Bio / 澳斯康生物
Auscan Biopharmaceuticals / Thousand Oaks Biopharmaceuticals (澳斯康生物, TOBio) is a Nantong-headquartered biologics CDMO and cell-culture-media group founded around 2011–2017. Through JSBio it supplies serum-free media for recombinant proteins, antibodies, vaccines and cell therapy; through its CDMO arm it offers CMC from cell-line development through clinical and commercial GMP manufacturing for mAbs, bispecifics, ADCs and related modalities at Nantong and Shanghai Lingang sites that target FDA/EMA/NMPA standards. The company lists global footprints in Jiangsu, Shanghai, Gansu, Korea and the US and has been recognized as a China unicorn / specialized SME while serving 500+ biopharma customers.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Nantong, China
- Employees
- 46
- Open positions
- 2
- Dealroom signal
- 77.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Developer Tools, Biotechnology, Rumoured $1B, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2019
- Capital deployed
- $59M
- Preferred round
- SERIES A
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| FundingOther financing | Jul 2022 | $0 | — | Timesbole | ↗ |
| SERIES DOther financing | Dec 2021 | $235M | $940M | CDH Investments · Highlight Capital · Hillhouse Capital · Goldstone Investment | ↗ |
Growth signals
Latest recorded traffic for Auscan Bio / 澳斯康生物 is 10 monthly website visits, down 98% over the last three months. Auscan Bio / 澳斯康生物's team grew 2.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
New Alliance Capital
BlueBay Asset Management- BCBinghong Capital
Addor Capital
CITIC Gold Stone Investment
CICC- GIGoldstone Investment
Series B and later5 investors entered at this stage
GL Ventures- CFCapital Venture Investment Fund
CDH Investments
Highlight Capital
Hillhouse Capital
Other known investors1 additional known investor
Timesbole
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Auscan Bio / 澳斯康生物 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Auscan Bio / 澳斯康生物’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.